<DOC>
	<DOCNO>NCT02033317</DOCNO>
	<brief_summary>This study assess pharmacodynamic effect patiromer serum potassium participant hemodialysis .</brief_summary>
	<brief_title>An Open-Label , Multiple Dose Study Evaluate Pharmacology , Safety , Tolerability Patiromer Participants Hemodialysis</brief_title>
	<detailed_description>The initial intent enroll 12-24 adult male female participant hemodialysis study . Due significant recruitment challenge , study discontinue six participant enrol study . This open-label , multiple-dose , adaptive-design study participant hemodialysis . Eligible participant hemodialysis remain Clinical Research Unit 2 week ( Day -7 Day 8 ) require consume potassium , magnesium , calcium sodium-controlled diet .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Participants hemodialysis age 18 70 year , serum potassium level least 5.5 mmol/L Adequately dialyze ( Kt/V â‰¥ 1.2 ) History bowel obstruction , swallow disorder , severe gastrointestinal disorder major gastrointestinal surgery . Severe constipation irregular bowel habit . Unable consume tolerate studyspecific diet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>